Cyclo Therapeutics announced that a phase 2b study for its investigational drug Trappsol Cyclo, which targets the reduction of amyloid beta and tau in the treatment of early Alzheimer’s disease, is now underway.
According to a Cyclo Therapeutics press release, the phase 2b study is a 6-month multicenter, randomized, placebo-controlled, double-blind study evaluating the safety, tolerability and possible efficacy of monthly Trappsol Cyclo (hydroxypropyl beta cyclodextrin) infusions in patients with early AD.
“The pathophysiology of AD is complex, and the relative contributions of the